FIELD: biotechnology.
SUBSTANCE: invention relates to protein engineering, biotechnology and medicine. Described is a recombinant protein presented on SEQ ID NO: 2, having the ability to effectively bind to the receptor-binding domain of the S-protein SARS-CoV-2. Disclosed is a recombinant plasmid pET39b-LCB1-ABD-Ba, which provides synthesis of recombinant protein in Escherichia coli cells, obtained by cloning a DNA fragment presented on SEQ ID NO: 1, into the plasmid vector pET39b at the NdeI/XhoI restriction sites. Disclosed is a recombinant strain Escherichia coli BL21(DE3)/pET39b-LCB1-ABD-Ba, containing recombinant plasmid pET39b-LCB1-ABD-Ba according to cl. 2 – producer of recombinant protein. Described is a method of producing recombinant protein from biomass of recombinant strain Escherichia coli BL21(DE3)/pET39b-LCB1-ABD-Ba, at which cell destruction by disintegration is carried out, cell debris is removed, protein is recovered by means of two-step chromatography, which includes a step of protein denaturation/renaturation on metal chelate affinity sorbent and purification by means of anion-exchange chromatography. Invention can find application in biotechnology and medicine when producing drugs against COVID-19.
EFFECT: invention enables to obtain a high level of induced synthesis – 40% of total cell protein and stable production, high specific antiviral activity, prolonged circulation time and antiviral effect in blood flow in comparison with Targevir1 analogue.
4 cl, 8 dwg, 1 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT SARS-CoV-2 S PROTEIN RBD-BINDING PROTEIN | 2022 |
|
RU2778942C1 |
| RECOMBINANT PLASMID PROVIDING SYNTHESIS OF BARNASE IN CELLS OF ESCHERICHIA COLI, ESCHERICHIA COLI STRAIN - PRODUCER OF BARNASE AND METHOD FOR PRODUCING BARNASE | 2017 |
|
RU2650871C1 |
| BROADLY NEUTRALIZING ANTIBODY AGAINST SARS-CoV-2 | 2022 |
|
RU2810476C1 |
| PLASMID GENETIC CONSTRUCT pET21_AB_CoV-2_1.3, WHICH ENSURES THE EXPRESSION OF RECOMBINANT PROTEIN AB_CoV-2_1.3 IN THE PROKARYOTIC SYSTEM OF E. COLI, AND RECOMBINANT PROTEIN AB_CoV-2_1.3, WHICH HAS THE PROPERTIES OF A SINGLE-DOMAIN NANOANTIBODY AGAINST SARS-CoV-2 | 2022 |
|
RU2798508C1 |
| ARTIFICIAL GENETIC CONSTRUCT FOR THE HETEROLOGOUS EXPRESSION OF THE S-PROTEIN RECEPTOR-BINDING DOMAIN IN A FUSED POLYPEPTIDE CHAIN WITH A NUCLEOCAPSID PROTEIN | 2022 |
|
RU2801597C1 |
| METHOD OF OBTAINING RECOMBINANT ANTIGEN MBP_RBD_6HIS OF SARS-CoV-2 VIRUS WITH C-TERMINAL AFFINITY TAG 6XHIS-TAG, INTENDED FOR USE AS COMPONENT OF REAGENT KIT FOR COVID-19 SERODIAGNOSTICS | 2023 |
|
RU2813324C1 |
| METHOD OF USING RECOMBINANT PROTEINS SARS-COV-2 AS PART OF A TEST SYSTEM FOR ELISA TEST WITH DETERMINING IGM, IGG, IGA CLASS ANTIBODY LEVELS IN BLOOD SERUM/PLASMA OF COVID-19 PATIENTS | 2020 |
|
RU2730897C1 |
| INTEGRATIVE PLASMID VECTOR pVEAL3-RBDdel, PROVIDING SYNTHESIS AND SECRETION OF RECOMBINANT PROTEIN OF RECEPTOR-BINDING DOMAIN RBDdelta OF CORONAVIRUS SARS-CoV-2 IN MAMMALIAN CELLS, RECOMBINANT CELL LINE STRAIN CHO-K1-RBDdelta AND RECOMBINANT PROTEIN RBDdelta SARS-CoV-2 PRODUCED BY CELL LINE STRAIN | 2023 |
|
RU2816175C1 |
| METHOD FOR DETERMINING THE ACTIVITY OF NEUTRALISING ANTIBODIES AGAINST SARS-CoV-2 IN THE SERUM OR PLASMA OF PEOPLE WITH PAST CASES OF COVID-19 OR VACCINATED WITH PREVENTIVE VACCINES AGAINST THE NOVEL CORONAVIRUS INFECTION COVID-19 USING A SET OF ENZYME IMMUNOASSAY REAGENTS CONTAINING A RECOMBINANT RECEPTOR-BINDING DOMAIN (RBD) OF SURFACE GLYCOPROTEIN S OF CORONAVIRUS SARS-CoV-2 AND RECOMBINANT HUMAN RECEPTOR ACE2 | 2021 |
|
RU2784655C1 |
| METHOD OF PRODUCING RECOMBINANT ANTI-TUMOR TOXIN BASED ON PROTEIN BARNASE-BARSTAR AND TARGETED POLYPEPTIDE DARPIN WITH EFFECT OF INSTANT CANCELLATION OF CYTOTOXIC ACTION | 2015 |
|
RU2610179C1 |
